AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 i...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for...
WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrate...
Axsome Biotherapeutics announced that the US regulator has granted Priority Review to its investigational therapy for agitation associated with Alzheimer...
Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Grou...
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submi...
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifida...
First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangio...
Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, a...
T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food an...
Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leader...
Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program Agreement Provides Tariff Re...
SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the Priority Review Voucher scheme is a lifeline for...
© 2026 Biopharma Boardroom. All Rights Reserved.
